RaQualia Pharma Inc.

4579・Growth Market・Pharmaceuticals

Official website

RaQualia Pharma Inc.

4579・Growth Market・Pharmaceuticals

Official website

RaQualia Pharma Inc.4579

RaQualia Pharma Inc.

4579Growth MarketPharmaceuticals

3rd Quarter of FY2026/12Earnings Release

Tegoprazan drives +20.6% growth in royalty revenue; hitting the full-year plan hinges on booking milestones and upfront payments in 4Q

November 13, 2026 at 23:50 GMT+9

RaQualia Pharma Inc.

4579Growth MarketPharmaceuticals

3rd Quarter of FY2026/12Earnings Preview

3Q will test tegoprazan royalty growth and the path to 2H milestone recognition, with the focus on whether the full-year profit plan is on solid footing

November 11, 2026 at 15:30 GMT+9

RaQualia Pharma Inc.

4579Growth MarketPharmaceuticals

2nd Quarter of FY2026/12Earnings Call

Tegoprazan US P3 shows +19.6pt superiority in severe EE healing rate; Lazarus out-licensing reactivates dormant assets; three-tier framework drives value visibility

August 18, 2026 at 20:17 GMT+9

RaQualia Pharma Inc.

4579Growth MarketPharmaceuticals

2nd Quarter of FY2026/12Earnings Release

Tegoprazan royalty income continues to expand at +14.4% YoY; structure geared toward achieving full-year profitability via milestone recognition in H2

August 14, 2026 at 19:32 GMT+9

RaQualia Pharma Inc.

4579Growth MarketPharmaceuticals

2nd Quarter of FY2026/12Earnings Preview

With tegoprazan capturing the top position in Korean outpatient prescriptions and progress in US FDA approval review, the focus turns to confirming revenue recovery and out-licensing expansion from 2Q onward

August 12, 2026 at 15:30 GMT+9